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and Maria Bishop2,3,4Abstract
Neuroblastoma is considered a pediatric malignancy as over 95% of cases are diagnosed in patients ≤10 years old.
This cancer is extremely rare in elderly patients. We conducted a Surveillance, Epidemiology, and End Results (SEER)
database analysis in the USA between 1973–2007 that revealed only 35 elderly patients (>60 years of age) with
neuroblastoma of whom only 2 patients had primary mediastinal neuroblastoma. There is a paucity of treatment and
survival outcomes data for the elderly owing to the rarity of neuroblastoma in this population. Currently there are no
standard guidelines or protocols for treatment of adult neuroblastoma. We report a rare and challenging case of an
86-year old patient presenting with mediastinal neuroblastoma and syndrome of inappropriate antidiuretic hormone
secretion (SIADH) successfully treated with resection. Herein, we also provide a review of the literature and updated
survival data on neuroblastoma based on results of our SEER database review.
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Neuroblastoma is the most common extracranial solid
tumor among infants and children [1]. It is almost ex-
clusively a pediatric neoplasm [2,3]: the median age at
diagnosis is 2 years, and more than 90% of patients are
diagnosed under ten years of age [1,3]. In patients over
30 years, it is rare (0.2 cases per million inhabitants per
year) and its incidence becomes increasingly scarce in the
elderly population [4]. Our review of literature revealed 35
elderly patients with neuroblastoma with only two prior
cases of mediastinal neuroblastoma. Our 86-year-old
patient is the oldest reported patient with mediastinal
neuroblastoma.
Neuroblastoma is a type of neuroblastic carcinoma that
can arise anywhere along the peripheral sympathetic
nervous system. It was first described by Dr. Rudolf* Correspondence: hanibabiker@email.arizona.edu
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unless otherwise stated.Virchow as a “glioma” in the abdominal cavity in 1864 [5].
By 1910, Dr. Homer-Wright determined that this tumor
originates from primitive neural cells based on the histo-
logical rosettes it forms within the bone marrow [6].
Histologically, neuroblastomas display a diverse spectrum
of differentiation. In well-differentiated tumors, cells
are approximately 7 to 10 microns in diameter, have hyper-
chromatic nuclei and scant cytoplasm, and may form
Homer-Wright rosettes. These rosettes are characterized
by a central lumen filled with neuropil, a delicate fibrillary
material consisting of neuronal processes, which are
surrounded by a halo of tumor cells [7]. Given that Homer-
Wright rosettes are also found in medulloblastomas and
peripheral primitive neuroectodermal tumors (PNET), it
is believed that their presence indicates neuronal differen-
tiation [7]. Yet, the cellular mechanisms responsible for
the formation of rosettes are not fully understood. Undif-
ferentiated neuroblastoma tumors are composed almost
entirely of neuroblasts with very few Schwannian (or stro-
mal) cells and are difficult to distinguish from other small
round blue cell tumors on light microscopy. Neuroblasto-
mas typically react with antibodies that distinguish neuralral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 CT scan of the chest. Sagittal CT scan image of the chest
reveals a large mediastinal mass measuring 5.2 × 4.7 cm. There is no
hilar or mediastinal lymphadenopathy.
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sin, chromogranin, and S100).
Neuroblastomas have a very broad spectrum of clinical
behavior, which can range from spontaneous regression,
to benign ganglioneuroma, or to aggressive disease with
metastatic dissemination leading to death. This diversity
correlates closely with numerous clinical and biological
factors (including patient age, tumor stage and histology,
and genetic abnormalities). One of the most important
prognostic factors is age at diagnosis. In the pediatric
population, the younger the child, the better is the prog-
nosis. Neuroblastomas in newborns often remit spontan-
eously. Children over 5 years old have an unfavorable
prognosis [8]. The natural history in adult and elderly
populations is unknown, given the rare incidence in
these groups. Polychemotherapy is the standard treatment
in children; however, there are no standard chemotherapy
protocols in elderly patients. In addition, review of case re-
ports and case series of neuroblastoma in elderly patients
indicate a different biology with a more indolent behavior
in comparison to children and adolescent patients [1-3].
Herein, we present a very rare case of neuroblastoma in
an elderly patient treated with surgical resection alone.
Presentation
An 86-year-old Hispanic male veteran presented to the
emergency room with fatigue, feeling “shaky” for five
days, and shortness of breath. His only medication was
amlodipine for hypertension, and his family history was
significant for a mother who died of lung cancer.
In the emergency room, his vital signs were stable and
his physical exam was only remarkable for minimally
reactive, asymmetric pupils. Lab studies disclosed sodium
of 128 mEq/L (reference range 135-145 mEq/L), plasma
osmolality of 266 mOsm/kg (284-306 mOsm/kg), urine
osmolality of 533 mOsm/kg (250-900 mOsm/kg), a urin-
ary sodium concentration of 103 mEq/L (40–220 mEq/l/
24 hours), and an alkaline phosphatase of 151 U/L
(40–125 U/L). Results of all other laboratory studies
were within normal ranges. A chest X-ray demonstrated
an enlarged mediastinum. Follow-up contrast-enhanced
chest computed tomography (CT) revealed an anterior
mediastinal mass measuring 5.2 × 4.7 cm in the sagittal
section (Figure 1). Staging contrast CT scan of his head
and abdomen/pelvis were negative. The patient was di-
agnosed with SIADH and was placed on fluid restriction,
which led to improvement of his sodium levels and abate-
ment of his symptoms. CT-guided fine needle aspiration
biopsy was performed and pathology revealed a poorly
differentiated neuroendocrine carcinoma. Immunohis-
tochemistry showed positive staining for synaptophysin
and chromogranin, focal positivity for MAK6 (pankeratin),
and absence of S-100. Based on the morphology and
immunoprofile, this tumor could either represent a primarythymic neuroendocrine carcinoma or metastatic large cell
neuroendocrine carcinoma of pulmonary origin. A whole-
body 18F-FDG-PET/CT scan demonstrated the anterior
mediastinal mass, measuring 5.0 × 5.1 cm with an SUVmax
of 15 (Figure 2). No additional pulmonary masses, suspi-
cious osseous lesions, or adenopathy were appreciated.
He was referred to cardiothoracic surgery and under-
went a sternotomy, “en bloc” thymectomy, and wedge
left pulmonary resection, all with negative margins.
Surgical pathology revealed a tan-red thymus with a firm
encapsulated nodule measuring 6.5 × 5.5 cm and areas
of hemorrhage. Microscopic extracapsular extension was
present with perithymic adipose infiltration and capsular
adherence to the pleura and pericardium, but lung tissue
and lymph nodes were not involved. The tumor cells had
a neuroendocrine appearance with abundant neutropil,
formed rosettes, and a low mitotic index (<2% of cells)
(Figure 3). Immunohistochemical staining revealed posi-
tive neuroendocrine markers: CD56, synaptophysin and
chromogranin in tumor cells, neurofilament protein in
neuropil, S-100 (focally), and negative cytokeratin AE1/
AE3 and GFAP. This pattern is typical for neuroblasto-
mas. The absence of cytokeratins excluded a diagnosis of
thymic carcinoma. The abundant presence of neuropil
and the absence of clear-cut membrane staining with
CD99 were sufficient to exclude PNET. Furthermore, the
interphase fluorescence in situ hybridization (FISH)
was negative for EWSR1 t(11;22)(q24;q12) translocation,
excluding Ewing’s sarcoma and supporting the diagnosis
Figure 2 Body PET scan pre-surgery. PET scan of the chest and body reveals an anterior mediastinal mass measuring 5.0 × 5.1 cm with an SUV
of 15. No additional suspicious masses or adenopathy are appreciated. There is an area of increased metabolic activity in the inferior aspect of the
right hepatic lobe that is related to bowel activity.
Figure 3 Resected mediastinal mass surgical pathology.
Hemotoxylin & Eosin stained section of resected mediastinal mass
reveals scattered small Homer-Wright rosettes (arrows): small dark
neuroblastoma cells in circular groups around pale fibrillary neuropil
(200× magnification).
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Neuroblastoma Staging System (INSS), our patient has a
stage 1 tumor.
The patient tolerated the surgical procedure without
complications and his sodium levels remained normal
without fluid restriction following surgery. Repeat PET scan
7 months after treatment indicated no mediastinal mass
or residual disease (Figure 4). The patient remains free of
disease and asymptomatic 11 months after resection.Discussion
Epidemiology
We obtained and analyzed neuroblastoma incidence from
the U.S. National Cancer Institute’s Surveillance, Epidemi-
ology, and End-Results registry (SEER). All neuroblastoma
cases diagnosed between 1973 and 2010 were selected,
yielding 3818 patients between the ages of 0 and 103 years.
The data was categorized according to demographic in-
formation, anatomic site, and interval disease-specific
Figure 4 Body PET scan post-surgery. PET scan of the chest and body performed 7 months after surgical resection reveals no foci of abnormal
FDG avid activity within the chest, no pulmonary nodules, and normal cardiomediastinal silhouette appearance.
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age at diagnosis was classified into three groups: <18 years,
18–60 years, and >60 years. Within the oldest group, data
were analyzed by gender, race, anatomic location, and
5-year DSS.
The SEER database included 3602 pediatric, 181 adult,
and 35 elderly patients (>60 years of age), representing
94.3%, 4.7%, and 0.9% of neuroblastoma cases, respectively
(Table 1). In elderly patients, 15 patients were male (43%)
and 20 were female (57%). Thirty patients were identified
as White (86%), 3 patients as Native American, Asian, or
Pacific Islander (8.6%), and 2 patients as Black (5.7%). The
most common primary sites in patients > 60 years of age
were soft tissue including the heart (60%), trachea and
respiratory organs including the mediastinum (31.4%),
and the testis (5.7%). Only 2 of the 3818 patients (0.05%)
were reported to be over 60 years old with a mediastinal
tumor site. Thus, our patient is extremely unique. He is
the third patient with these characteristics and is the
eldest of them.Clinical presentation
The clinical presentation of neuroblastoma reflects the
tumor’s primary location and extent of metastatic disease, if
present. Patients with localized disease can be asymptom-
atic whereas patients with advanced disease can appear
systemically ill. Based on our SEER data, neuroblastomas
most frequently originate in endocrine tissues including
the adrenal glands, soft tissues, and the retroperitoneum.
These tumors metastasize to bone marrow (70.5%), bone
(55.7%), lymph nodes (30.9%), liver (29.6%), intracranial
and orbital sites (18.2), lung (3.3%), and the central ner-
vous system (0.6%) [9]. The sites of the primary tumor
and metastases correlate with the most common signs
and symptoms, which include weight loss, abdominal pain
and distention, back pain, weakness, spinal compres-
sion, anemia, and hypertension [9]. Horner’s syndrome
is described with cervical sympathetic ganglia involvement.
Children are more likely than the elderly to present with
widespread and severe symptoms, as pediatric neuroblasto-
mas metastasize frequently and rapidly. Additionally,
Table 1 SEER database analysis of neuroblastoma patient characteristics between 1973–2010 according to age distribution
<18 years 18-60 years >60 years
Number of patients 3602 181 35
Gender (%) Male 53% 51% 43%
Female 47% 49% 57%
Race (%) White 81% 77% 86%
Black 12% 15% 5.7%
Other 7% 8% 8.6%
MCPS (%) 1ST MCPS Endocrine including Thymus (42.9%) Central Nervous System (39%) Soft tissue including heart (60%)
2nd MCPS Soft Tissue including heart (23.6%) Retroperitonium (17%) Trachea, mediastinum and
respiratory organs (31.4%)
3rd MCPS Retroperitonium (12.4%) Endocrine including Thymus (14%) Testis (5.7%)
4TH MCPS Trachea, Mediastinum and Respiratory
Organs (9.5%)
Soft Tissue including heart (7.7%) Stomach (2.9%)
5 year DSS 46.9% 32.6% 40%
MCPS: Most Common Primary Site; DSS: Disease specific survival.
Bold data highlights SEER data base analysis results in patients older than 60 years of age.
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(homovanillic acid, vanillylmandelic acid, or dopamine),
which can cause hypertension [2]. Multiple studies suggest
that adult patients rarely have positive urine catechol-
amine tests [2,10].
Our 86-year old patient with Stage 1 mediastinal neuro-
blastoma presented with vague complaints of weakness,
shakiness, and weight loss with moderate hyponatremia.
His SIADH resolved after the tumor’s excision, suggesting
a paraneoplastic etiology. Interestingly, a paraneoplastic
SIADH syndrome has been described in 83% of medias-
tinal and thymic neuroblastomas in elderly patients
whereas few of the other cancers occurring in the medi-
astinum secrete ectopic ADH [10-13]. A review of the
literature revealed five elderly thymic neuroblastoma
patients, ages 60–80, with proven paraneoplastic SIADH
[10,11,13]. Of these, one patient presented similarly to our
patient with weakness, memory loss, and severe hypona-
tremia [10]. Another had symptoms of SIADH and coron-
ary artery disease [13]. Both had resolution of SIADH
following resection. The other cases of neuroblastoma
were otherwise asymptomatic. Although neuroblastomas
in elderly patients are exceedingly rare, they should be
considered as a diagnostic possibility. This is especially
true for patients with SIADH and a mediastinal mass.
Prognosis
Neuroblastomas have a very broad spectrum of clinical
behavior, which can include spontaneous regression, matur-
ation to a benign ganglioneuroma, or aggressive disease
with metastatic dissemination leading to death. The clinical
array correlates closely with numerous clinical and bio-
logical factors. The International Neuroblastoma Pathology
Classification system, developed in 1999, evaluates progno-
sis of childhood neuroendocrine tumors based on thepatient’s age at diagnosis and morphology (characterization
of stroma, grade of differentiation, and mitosis-karyorrhexis
index [MKI]) [8]. The most important prognostic factor for
this system is age at diagnosis. It awards the best prognosis
to newborns, followed by infants, then toddlers. Children
over age 5 are given an unfavorable prognosis regardless of
histology. If this tool is applied to our 86-year old patient,
it yields contrasting results. Our patient’s overall five-year
survival would be estimated at 0% even though his
pathology (schwannian stroma-poor morphology, cellular
differentiation falling in the continuum between poorly
differentiated and differentiated subtypes, and low MKI
of <2%) would confer a favorable prognosis [8]. Based on
this, we conclude that this classification system cannot be
used reliably in older patients.
Limited prognostic data exists for adolescents, adults,
and the elderly. However, it is clear that the natural history
of neuroblastoma of the elderly differs from that of chil-
dren. In these populations, the cancer has more indolent
behavior, but carries a worse prognosis [2]. This is most
likely attributable to the multiple comorbidities of this
population and the concomitant inability to tolerate
aggressive systemic therapy. Although mediastinal neuro-
blastoma appears to have a better prognosis in the elderly
in comparison to other groups according to our review and
published case reports, the rarity of this disease precludes a
survival analysis in a clinical trial. Cytologic atypia and high
mitotic activity were correlated with a more aggressive
tumor behavior by a retrospective case series of 22 adult
and elderly patients with thymic neuroblastoma [1].
Our SEER database analysis also demonstrates that eld-
erly patients have a different disease course than children.
We observed that all ages of neuroblastoma patients with
any tumor location have a 5-year DSS of 40%. Pediatric
patients have a 5-year DSS of 46.9%. In the elderly, the
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mediastinal, tracheal, and other respiratory neuroblasto-
mas had improved outcomes and the elderly fared better.
Of 353 patients with neuroblastoma at these sites between
the ages of 0–73, the 5-year DSS was 66% for all ages,
67% for the 342 pediatric patients, 44% for the 9 adult
patients, and 100% in the 2 elderly patients. Despite the
extremely limited data of the elderly with mediastinal
neuroblastomas, the survival difference between the pe-
diatric and elderly groups concurs with the proposal of a
more prolonged tumor progression in the elderly [2].
Another study reported that adult and elderly patients
had a longer interval from symptom onset to diagnoses
and from recurrence/progression to death [3]. This effect
may be attributed to the rarity of metastasis or infrequency
of MYCN gene amplification in older patients [12,14].
Treatment strategies and survival data
Neuroblastoma treatment in pediatric populations is well-
studied but remains complex and difficult. Surgical resec-
tion is the mainstay of treatment in low-risk patients,
with optional combination chemotherapy including cyclo-
phosphamide, carboplatin, cisplatin, etoposide, teniposide,
and doxorubicin. Infants can be observed for spontaneous
remission or progression. Radiotherapy is recommended
only if the disease progresses despite surgery and chemo-
therapy. For high-risk pediatric patients, an aggressive com-
bined modality approach, including surgical resection,
high-dose chemotherapy with stem cell rescue, radiation
therapy and biologic/immunologic therapy has shown
improved long-term outcomes [15]. Nevertheless, most
high-risk patients eventually relapse and die of their disease.
In a Memorial-Sloan Kettering retrospective review of
30 patients with advanced neuroblastoma, aged 12–41 at
diagnosis, high-dose induction chemotherapy followed
by surgery was shown to achieve a minimal disease state
in over 50% of patients [1]. Additionally they found that:
1) 3F8 immunotherapy is helpful in chemo-resistant
neuroblastoma; 2) moderate doses of local radiation
(21 Gy) aid in achieving local control; 3) standard-dose
chemotherapy only has a palliative role; and 4) anti-GD2
antibodies, cis-retinoic acid, oral etoposide, and topotecan
provide the basis of a multi-modality approach and
improve the poor prognosis.
Another group performed a retrospective review of 27
adolescent and adult neuroblastoma patients who did
not have MYCN oncogene amplification. This population
ranged from 12–69 years of age at diagnosis, although the
distribution was skewed towards the younger end of this
range, with a median age of 17 years. They used surgery
alone for stage I tumors and surgery followed by radio-
therapy for stage II disease. Stage III patients were
given induction therapy with 6 cycles of neoadjuvant
cisplatin plus etoposide alternated with adriamycin,cyclophosphamide and vincristine, followed by either
surgery or 35–45 Gy radiotherapy; they then underwent
consolidation with hemi-body irradiation and four cycles of
the alternating chemotherapy regimen [3]. For stage IV, the
protocol for stage III was used, with the subsequent
addition of intensified chemotherapy and radiotherapy
protocols. They found 5-year OS rates of 83% and 28% for
patients staged I-II and III-IV, respectively. Additionally,
elderly patients had a longer interval between recurrence
or progression and death, which they speculate is due to
the lack of MYCN amplification. This mutation occurs
in 25-40% of high-risk pediatric tumors and correlates
with rapidly progressive tumor behavior [14,16]. Interest-
ingly, the vast majority of adult neuroblastomas lack the
MYCN amplification [1-3,12,14].
Currently, there is a paucity of treatment and survival
outcome data for the elderly owing to the rarity of neuro-
blastoma in this population. There are no standard treat-
ment guidelines or chemotherapy protocols. Expert opinion
suggests surgical tumor resection. When surgical margins
and lymph nodes are negative, as in our patient, this
approach can result in long-term relapse-free survival.
Several case reports and case series reported patients as
disease-free up to 108 months after surgical tumor exci-
sion [2,3,10-12]. The intense pediatric protocols are poorly
tolerated by elderly patients. Discontinuing those proto-
cols most likely contributed to the improved survival
trend of elderly neuroblastoma patients over the past
decade as observed by a SEER database review of patients
diagnosed between 1973–2010 [4]. Hence, surgical resec-
tion is the main treatment and adjuvant chemotherapy or
radiotherapy is reserved for advanced stage disease.
Conclusion
Mediastinal neuroblastoma in elderly patients is a very
rare disease with sparse data available in the literature
pertaining to the epidemiology, treatment, and outcomes.
Early stage mediastinal neuroblastoma in elderly patients
can be managed with surgical resection alone, due to the
fact that this disease has a different biology and more
indolent behavior than is observed in pediatric patients.
In addition, elderly patients cannot tolerate aggressive
chemotherapy regimens offered to pediatric patients.
Several case reports indicated a disease-specific survival
ranging from 12 to 108 months in this population after
surgical resection. Herein we report a case of the oldest
patient with early stage mediastinal neuroblastoma suc-
cessfully treated with surgical resection alone.
Consent
Written informed consent was obtained from the patient
for publication of this case report and the accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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